Biomarin Pharmaceutical Inc (BMRN)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands 595,138 594,627 594,116 593,605 593,095 592,586 1,084,990 1,084,010 1,083,020 1,082,030 1,081,050 1,080,060 1,079,080 1,078,090 1,077,110 1,076,130 1,075,140 1,074,160 1,073,200 486,713
Total stockholders’ equity US$ in thousands 5,657,990 5,413,400 5,286,300 5,073,820 4,951,550 4,896,900 4,782,830 4,659,040 4,603,160 4,568,510 4,499,740 4,386,240 4,265,670 4,261,080 4,236,500 4,162,010 4,100,930 4,053,890 3,236,680 3,239,960
Debt-to-equity ratio 0.11 0.11 0.11 0.12 0.12 0.12 0.23 0.23 0.24 0.24 0.24 0.25 0.25 0.25 0.25 0.26 0.26 0.26 0.33 0.15

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $595,138K ÷ $5,657,990K
= 0.11

The debt-to-equity ratio of Biomarin Pharmaceutical Inc has been consistently decreasing from 0.15 as of March 31, 2020, to 0.11 as of December 31, 2024. This indicates a decreasing reliance on debt financing relative to equity over the years. A lower debt-to-equity ratio signifies a lower level of financial risk and a stronger financial position for the company. The trend suggests that Biomarin Pharmaceutical Inc has been effectively managing its debt levels while maintaining a healthy balance between debt and equity in its capital structure. The decreasing ratio can be seen as a positive indicator of the company's financial stability and prudent financial management.